1. Home
  2. XAIR vs EOCN Comparison

XAIR vs EOCN Comparison

Compare XAIR & EOCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beyond Air Inc.

XAIR

Beyond Air Inc.

N/A

Current Price

$2.07

Market Cap

3.0M

Sector

Health Care

ML Signal

N/A

EOCN

Eocene Ltd. Ordinary Shares

N/A

Current Price

$2.25

Market Cap

2.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XAIR
EOCN
Founded
2011
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0M
2.9M
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
XAIR
EOCN
Price
$2.07
$2.25
Analyst Decision
Buy
Analyst Count
2
0
Target Price
★ $20.00
N/A
AVG Volume (30 Days)
★ 50.6K
6.7K
Earning Date
11-11-2026
11-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $7,679,000.00
N/A
Revenue This Year
$6.52
N/A
Revenue Next Year
$104.36
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 107.26
N/A
52 Week Low
$0.33
$2.05
52 Week High
$8.19
$3.80

Technical Indicators

Market Signals
Indicator
XAIR
EOCN
Relative Strength Index (RSI) 40.75 34.58
Support Level $2.05 $2.32
Resistance Level $2.49 $2.98
Average True Range (ATR) 0.29 0.29
MACD 0.04 -0.03
Stochastic Oscillator 13.74 30.08

Price Performance

Historical Comparison
XAIR
EOCN

About XAIR Beyond Air Inc.

Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.

About EOCN Eocene Ltd. Ordinary Shares

Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. Its wholly owned subsidiary develops medical devices for postoperative colorectal care, including CG-100, an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas. The company's therapeutic portfolio includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers.

Share on Social Networks: